Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma.

Kim MY, Sposto R, Swaika A, Asano H, Alamgir A, Chanan-Khan A, Ailawadhi S.

Oncology. 2014 Jul 18;87(4):224-231. [Epub ahead of print]

PMID:
25059308
[PubMed - as supplied by publisher]
2.

Outcome Disparities among Ethnic Subgroups of Waldenström's Macroglobulinemia: A Population-Based Study.

Ailawadhi S, Kardosh A, Yang D, Cozen W, Patel G, Alamgir MA, Chanan-Khan AA.

Oncology. 2014;86(5-6):253-62. doi: 10.1159/000360992. Epub 2014 Jun 4.

PMID:
24902770
[PubMed - in process]
3.

The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.

Hallek M, Kay NE, Osterborg A, Chanan-Khan AA, Mahler M, Salman M, Wan Y, Sun S, Zhuang SH, Howes A.

Future Oncol. 2014 Jun 5:1-9. [Epub ahead of print]

PMID:
24901734
[PubMed - as supplied by publisher]
Free Article
4.

Implementing individualized medicine into the medical practice.

Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW, Lindor NM, McCormick JB, McWilliams RR, Parker AS, Riegert-Johnson DL, Rohrer Vitek CR, Schahl KA, Schultz C, Stewart K, Then GC, Wieben ED, Farrugia G.

Am J Med Genet C Semin Med Genet. 2014 Mar;166C(1):15-23. doi: 10.1002/ajmg.c.31387. Epub 2014 Mar 10.

PMID:
24616301
[PubMed - in process]
5.

The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.

Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A.

Br J Haematol. 2014 Apr;165(1):78-88. doi: 10.1111/bjh.12731. Epub 2014 Jan 27.

PMID:
24467634
[PubMed - indexed for MEDLINE]
6.

AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.

Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A.

Br J Haematol. 2014 Feb;164(3):352-65. doi: 10.1111/bjh.12633. Epub 2013 Nov 17.

PMID:
24236538
[PubMed - indexed for MEDLINE]
7.

Smoldering multiple myeloma requiring treatment: time for a new definition?

Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R, Kapoor P, Bergsagel PL, McCurdy A, Gertz MA, Lacy MQ, Lust JA, Russell SJ, Zeldenrust SR, Reeder C, Roy V, Buadi F, Dingli D, Hayman SR, Leung N, Lin Y, Mikhael J, Kumar SK.

Blood. 2013 Dec 19;122(26):4172-81. doi: 10.1182/blood-2013-08-520890. Epub 2013 Oct 21. Review.

PMID:
24144641
[PubMed - indexed for MEDLINE]
8.

Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.

Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.

Br J Haematol. 2013 Nov;163(4):478-86. doi: 10.1111/bjh.12565. Epub 2013 Sep 25.

PMID:
24112026
[PubMed - indexed for MEDLINE]
9.

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma.

Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ.

Blood Cancer J. 2013 Sep 6;3:e143. doi: 10.1038/bcj.2013.38.

PMID:
24013664
[PubMed]
Free PMC Article
10.

IMWG consensus on risk stratification in multiple myeloma.

Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group.

Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. Review.

PMID:
23974982
[PubMed - indexed for MEDLINE]
11.

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics.

Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S.

Blood Cancer J. 2013 Jun 28;3:e121. doi: 10.1038/bcj.2013.19.

PMID:
23811785
[PubMed]
Free PMC Article
12.

Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells.

Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2014 Mar;55(3):652-61. doi: 10.3109/10428194.2013.807927. Epub 2013 Jul 1.

PMID:
23721511
[PubMed - in process]
13.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S.

Leukemia. 2013 Dec;27(12):2351-6. doi: 10.1038/leu.2013.152. Epub 2013 May 14.

PMID:
23670297
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ; Mayo Clinic.

Mayo Clin Proc. 2013 Apr;88(4):360-76. doi: 10.1016/j.mayocp.2013.01.019. Erratum in: Mayo Clin Proc. 2013 Jul;88(7):777. Stewart, Keith [corrected to Stewart, A Keith].

PMID:
23541011
[PubMed - indexed for MEDLINE]
15.

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J, Orlowski RZ, Shah JJ; International Myeloma Working Group.

Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. Review.

PMID:
23288300
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S.

Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.

PMID:
22833546
[PubMed - indexed for MEDLINE]
Free Article
17.

Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.

Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA.

Leuk Lymphoma. 2013 Feb;54(2):387-96. doi: 10.3109/10428194.2012.713481. Epub 2012 Aug 27.

PMID:
22812491
[PubMed - indexed for MEDLINE]
18.

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.

Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foà R, Hellmann A, Dimopoulos M, Swern AS, Knight R.

Int J Hematol. 2012 Aug;96(2):254-62. doi: 10.1007/s12185-012-1125-7. Epub 2012 Jul 3.

PMID:
22752567
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Cancer- and chemotherapy-induced anemia.

Rodgers GM 3rd, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd.

J Natl Compr Canc Netw. 2012 May;10(5):628-53.

PMID:
22570293
[PubMed - indexed for MEDLINE]
20.

The proteasome activator PA200 regulates tumor cell responsiveness to glutamine and resistance to ionizing radiation.

Blickwedehl J, Olejniczak S, Cummings R, Sarvaiya N, Mantilla A, Chanan-Khan A, Pandita TK, Schmidt M, Thompson CB, Bangia N.

Mol Cancer Res. 2012 Jul;10(7):937-44. doi: 10.1158/1541-7786.MCR-11-0493-T. Epub 2012 May 1. Erratum in: Mol Cancer Res. 2012 Nov;10(11):1509.

PMID:
22550082
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk